Patents by Inventor David F. Carmichael

David F. Carmichael has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized anti-CD30 antibodies
    Patent number: 9574006
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: February 21, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Modified FC molecules
    Patent number: 9040041
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 26, 2015
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
  • Optimized Anti-CD30 Antibodies
    Publication number: 20120014943
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-Iu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Optimized anti-CD30 antibodies
    Patent number: 7973136
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: July 5, 2011
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • MODIFIED Fc MOLECULES
    Publication number: 20100249382
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Application
    Filed: June 4, 2010
    Publication date: September 30, 2010
    Inventors: JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, JOHN O. RICHARDS, GREGORY L. MOORE, DAVID F. CARMICHAEL
  • Pharmaceutical Compositions for the Treatment of TNF-Alpha Related Disorders
    Publication number: 20100222272
    Abstract: The invention relates to a pharmaceutical composition comprising a variant TNF-? protein that inhibits the activity of soluble TNF-? while substantially maintaining the activity of transmembrane TNF-?, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.
    Type: Application
    Filed: January 25, 2010
    Publication date: September 2, 2010
    Inventors: John R. Desjarlais, Paul Michael Steed, Jonathan Zalevsky, David Edmund Szymkowski, David F. Carmichael
  • Pharmaceutical compositions for the treatment of TNF-? related disorders
    Patent number: 7662367
    Abstract: The invention relates to a pharmaceutical composition comprising a variant TNF-? protein that inhibits the activity of soluble TNF-? while substantially maintaining the activity of transmembrane TNF-? a buffer and a tonicity agent wherein said composition has a pH from approximately 5.0 to 8.0.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: February 16, 2010
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Paul Michael Steed, Jonathan Zalevsky, David Edmund Szymkowski, David F. Carmichael
  • Optimized Anti-Cd30 Antibodies
    Publication number: 20080267976
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: October 6, 2006
    Publication date: October 30, 2008
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Fc variants with optimized Fc receptor binding properties
    Publication number: 20080206867
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 28, 2008
    Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
  • Pharmaceutical compositions for the treatment of TNF-alpha related disorders
    Publication number: 20080187509
    Abstract: The invention relates to a pharmaceutical composition comprising a variant TNF-? protein that inhibits the activity of soluble TNF-? while substantially maintaining the activity of transmembrane TNF-?, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.
    Type: Application
    Filed: June 22, 2006
    Publication date: August 7, 2008
    Inventors: John R. Desjarlais, Paul Michael Steed, Jonathan Zalevsky, David Edmund Szymkowski, David F. Carmichael
  • Human collagenase inhibitor, recombinant vector system for using same and recombinant DNA method for the manufacture of same
    Patent number: 6800732
    Abstract: A portable DNA sequence is disclosed which is capable of directing intracellular production of metalloproteinase inhibitors. Vectors containing this portable DNA sequence are also set forth, including the vector pUC9-F5/237P10 (ATCC Accession No. 53003). A recombinant-DNA method for the microbial production of a metalloproteinase inhibitor, which method incorporates at least one of the portable DNA sequences and the vectors disclosed herein.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: October 5, 2004
    Assignee: Amgen Inc.
    Inventors: David F. Carmichael, David C. Anderson, George P. Stricklin, Howard G. Welgus
  • &agr;2-macroglobulin receptor as a receptor for CTGF
    Patent number: 6555322
    Abstract: The invention provides a connective tissue growth factor (CTGF) receptor and biochemical and/or biological equivalents, homologs, derivatives, subunits, fragments, and complexes thereof. The CTGF receptor is useful in the treatment and diagnosis of CTGF-associated disorders and in methods of screening for agents that effect CTGF receptor expression and activity. The invention further provides nucleic acid sequences encoding the CTGF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, antisense sequences and antibodies directed against CTGF receptor, and pharmaceutical compositions for use in treatment of CTGF-associated disorders.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: April 29, 2003
    Assignee: FibroGen, Inc.
    Inventors: Patricia R. Segarini, James E. Nesbitt, David F. Carmichael
  • Human collagenase inhibitor, recombinant vector system for using same and recombinant DNA method for the manufacture of same
    Publication number: 20030003556
    Abstract: A portable DNA sequence is disclosed which is capable of directing intracellular production of metalloproteinanse inhibitors. Vectors containing this portable DNA sequence are also set forth, including the vector pUC9-F5/237P10 (ATCC Accession No. 53003). A recombinant-DNA method for the microbial production of a metalloproteinase inhibitor, which method incorporates at least one of the portable DNA sequences and the vectors disclosed herein.
    Type: Application
    Filed: November 14, 2001
    Publication date: January 2, 2003
    Applicant: AMGEN INC.
    Inventors: David F. Carmichael, David C. Anderson, George P. Stricklin, Howard G. Welgus
  • Connective tissue growth factor (CTGF) and methods of use
    Publication number: 20020142353
    Abstract: The present invention provides rat connective tissue growth factor (CTGF), means for producing CTGF and therapeutic methods for using CTGF or derivatives therof. The invention further provides methods for modulating the activity of CTGF and methods for ameliorating a cell proliferative disorder associated with CTGF.
    Type: Application
    Filed: March 18, 2002
    Publication date: October 3, 2002
    Applicant: FibroGen, Inc.
    Inventors: Brian Frederick Schmidt, Margaret Leah Allen, Fran S. Sverdrup, David F. Carmichael
  • Connective tissue growth factor (CTGF) and methods of use
    Patent number: 6358741
    Abstract: The present invention provides rat connective tissue growth factor (CTGF), means for producing CTGF and therapeutic methods for using CTGF or derivatives therof. The invention further provides methods for modulating the activity of CTGF and methods for ameliorating a cell proliferative disorder associated with CTGF.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: March 19, 2002
    Assignee: Fibrogen Inc.
    Inventors: Brian Frederick Schmidt, Margaret Leah Allen, Fran Sverdrup, David F. Carmichael
  • Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
    Publication number: 20020028847
    Abstract: The present invention is directed to methods for treating fibrosis related diseases and disorders, particularly scleroderma by treating a patient in need with a pharmaceutically efficacious amount of a prostacyclin derivative. The most preferred prostacyclin derivatives are cicaprost and iloprost.
    Type: Application
    Filed: July 25, 2001
    Publication date: March 7, 2002
    Applicant: Fibrogen, Inc.
    Inventors: Richard Stratton, Carol Black, George R. Martin, David F. Carmichael
  • Human collagenase inhibitor, recombinant vector system for using same and recombinant-DNA method for the manufacture of same
    Patent number: 6342374
    Abstract: A portable DNA sequence is disclosed which is capable of directing intracellular production of metalloproteinanse inhibitors. Vectors containing this portable DNA sequence are also set forth, including the vector pUC9-F5/237P10 (ATCC Accession No. 53003). A recombinant-DNA method for the microbial production of a metalloproteinase inhibitor, which method incorporates at least one of the portable DNA sequences and the vectors disclosed herein.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: January 29, 2002
    Assignee: Amgen Inc.
    Inventors: David F. Carmichael, David C. Anderson, George P. Stricklin, Howard G. Welgus
  • METHOD FOR TREATMENT OF FIBROSIS RELATED DISEASES BY THE ADMINISTRATION OF PROSTACYCLIN DERIVATIVES
    Publication number: 20010006979
    Abstract: The present invention is directed to methods for treating fibrosis related diseases and disorders, particularly scleroderma by treating a patient in need with a pharmaceutically efficacious amount of a prostacyclin derivative. The most preferred prostacyclin derivatives are cicaprost and iloprost.
    Type: Application
    Filed: July 8, 1999
    Publication date: July 5, 2001
    Inventors: RICHARD STRATTON, CAROL M. BLACK, GEORGE R. MARTIN, DAVID F. CARMICHAEL
  • Method for treating interleukin-1 mediated diseases
    Patent number: 6159460
    Abstract: The present invention provides methods for treating interleukin-1 mediated diseases including arthritis, inflammatory bowel disease, sepsis and septic shock, ischemia injury, reperfusion injury, multiple sclerosis and cerebral infarctions such as cerebral palsy. The methods are accomplished by administering to a patient in need thereof a therapeutically effective amount of an interleukin-1 inhibitor.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: December 12, 2000
    Assignee: Amgen Inc.
    Inventors: Robert C. Thompson, David F. Carmichael
  • Human collagenase inhibitor sequence, recombinant vector system for using same and recombinant-DNA method for the manufacture of same
    Patent number: 6090585
    Abstract: A portable DNA sequence is disclosed which is capable of directing intracellular production of metalloproteinanse inhibitors. Vectors containing this portable DNA sequence are also set forth, including the vector pUC9-F5/237P10 (ATCC Accession No. 53003). A recombinant-DNA method for the microbial production of a metalloproteinase inhibitor, which method incorporates at least one of the portable DNA sequences and the vectors disclosed herein is described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 18, 2000
    Assignee: Amgen Inc.
    Inventors: David F. Carmichael, David C. Anderson, George P. Stricklin, Howard G. Welgus